198 related articles for article (PubMed ID: 32870250)
1. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R; Alsina L; Azar A; Bertrand Y; Bolyard AA; Dale DC; Deyà-Martinez À; Dickerson KE; Ezra N; Hasle H; Kang HJ; Kiani-Alikhan S; Kuijpers TW; Kulagin A; Langguth D; Levin C; Neth O; Olbrich P; Peake J; Rodina Y; Rutten CE; Shcherbina A; Tarrant TK; Vossen MG; Wysocki CA; Belschner A; Bridger GJ; Chen K; Dubuc S; Hu Y; Jiang H; Li S; MacLeod R; Stewart M; Taveras AG; Yan T; Donadieu J
Blood; 2024 Apr; ():. PubMed ID: 38643510
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
[TBL] [Abstract][Full Text] [Related]
4. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
9. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
Blood; 2023 Jun; 141(26):3232. PubMed ID: 37383001
[No Abstract] [Full Text] [Related]
10. Plerixafor for the Treatment of WHIM Syndrome.
McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Dale DC; Bolyard AA; Kelley ML; Westrup EC; Makaryan V; Aprikyan A; Wood B; Hsu FJ
Blood; 2011 Nov; 118(18):4963-6. PubMed ID: 21835955
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice.
Majumdar S; Gao JL; Pontejo SM; Balabanian K; Bachelerie F; Murphy PM
Immunohorizons; 2022 Jul; 6(7):543-558. PubMed ID: 35882421
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.
Dotta L; Notarangelo LD; Moratto D; Kumar R; Porta F; Soresina A; Lougaris V; Plebani A; Smith CIE; Norlin AC; Gòmez Raccio AC; Bubanska E; Bertolini P; Amendola G; Visentini M; Fiorilli M; Venuti A; Badolato R
J Allergy Clin Immunol Pract; 2019; 7(5):1568-1577. PubMed ID: 30716504
[TBL] [Abstract][Full Text] [Related]
14. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
15. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Badolato R; Dotta L; Tassone L; Amendola G; Porta F; Locatelli F; Notarangelo LD; Bertrand Y; Bachelerie F; Donadieu J
J Pediatr; 2012 Oct; 161(4):763-5. PubMed ID: 22748845
[TBL] [Abstract][Full Text] [Related]
16. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.
Gao JL; Owusu-Ansah A; Paun A; Beacht K; Yim E; Siwicki M; Yang A; Liu Q; McDermott DH; Murphy PM
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31687976
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
Kallikourdis M; Trovato AE; Anselmi F; Sarukhan A; Roselli G; Tassone L; Badolato R; Viola A
Blood; 2013 Aug; 122(5):666-73. PubMed ID: 23794067
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
[TBL] [Abstract][Full Text] [Related]
19. A WHIM satisfactorily addressed.
Broxmeyer HE
Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
[TBL] [Abstract][Full Text] [Related]
20. Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients.
Tassone L; Moratto D; Vermi W; De Francesco M; Notarangelo LD; Porta F; Lougaris V; Facchetti F; Plebani A; Badolato R
Blood; 2010 Dec; 116(23):4870-3. PubMed ID: 20736454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]